Analyst Reco. Harrow, Inc.

Equities

HROW

US4158581094

Market Closed - OTC Markets Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
17.89 ^USD	+2.23%		+6.74%	+59.73%

May. 15	B. Riley Raises Price Target on Harrow Health to $29 From $26, Keeps Buy Rating	MT
May. 14	Transcript : Harrow, Inc., Q1 2024 Earnings Call, May 14, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

B. Riley Raises Price Target on Harrow Health to $29 From $26, Keeps Buy Rating	May. 15	MT
Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	Apr. 11	MT
B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	Mar. 22	MT
B. Riley Lowers Harrow's PT to $30 From $45 After Lower-Than-Expected Q3 Results, Reduced Q4 Guidance; Keeps Buy Rating	Nov. 14	MT
B. Riley Raises Harrow Health's PT to $45 From $42 on Heels of Announced Transactions With Santen, Novaliq; Keeps Buy Rating	23-07-20	MT
B. Riley Raises Harrow Health's Price Target to $42 From $24, Keeps Buy Rating	23-05-04	MT
Lake Street Adjusts Price Target on Harrow Health to $37 From $24, Maintains Buy Rating	23-04-17	MT
B. Riley Lifts Harrow Health's PT to $24 From $22 Accounting for Additional Incremental Revenues From Fab-Five Products, Ramp Up of IHEEZO Sales Trajectory in 2024; Keeps Buy Rating	23-03-27	MT
B. Riley Raises Harrow Health's PT to $22 From $17 on Heels of Acquisition of 5 New Ophthalmology Products, Keeps Buy Rating	23-01-05	MT
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and 'BB' Rating from Egan-Jones	22-12-15	AQ
B. Riley Securities Resumes Harrow Health at Buy with $17 Price Target, Says Well-Positioned to Maintain Robust Momentum	22-09-08	MT
B. Riley Raises Harrow Health's Price Target to $20 from $17 After Higher-than-Expected Q1 Revenue, Keeps Buy Rating	22-05-20	MT
HARROW HEALTH : B. Riley Resumes Harrow Health at Buy with $16 PT, Says Well-Positioned to Maintain Momentum with Recent Q2 Beat, M&A Execution	21-10-14	MT
HARROW HEALTH : Aegis Capital Starts Harrow Health at Buy with $15 Price Target	21-09-24	MT
Harrow Health : Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-Jones (Form 8-K)	21-06-14	PU
HARROW HEALTH : B. Riley Adjusts Harrow Health's Price Target to $14 From $12, Keeps Buy Rating	21-01-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer